title: Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
abstract: BACKGROUND
  Few large clinical studies have evaluated whether switching tumour necrosis factor antagonists (anti-TNFs) is likely to improve psoriasis in patients with prior anti-TNF treatment.
  
  
  OBJECTIVE
  The aim of this subanalysis of the BELIEVE study was to assess the efficacy and safety of adalimumab for psoriasis in patients with and without previous anti-TNF treatment.
  
  
  METHODS
  The BELIEVE study enrolled patients with moderate to severe psoriasis and prior failure, intolerance or contraindication to ≥2 systemic therapies. In this 16-week, double-blind, randomized, controlled trial, patients received adalimumab (80 mg, week 0; 40 mg every other week, weeks 1-15) with either topical vehicle or topical calcipotriol/betamethasone dipropionate (C/B) applied once daily for 4 weeks, then as needed. The primary endpoint was ≥75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) at week 16. This post hoc subanalysis evaluated the safety and efficacy of adalimumab, with and without topical therapy, in BELIEVE patients who had prior exposure to anti-TNFs.
  
  
  RESULTS
  Of 730 patients enrolled, 282 (38.6%) had prior anti-TNFs and 448 (61.4%) were anti-TNF-naïve. Combining topical vehicle and topical C/B study populations, 61.7% of patients with prior anti-TNFs achieved PASI 75 at week 16, compared with 71.7% of anti-TNF-naïve patients (P=0.095). Adalimumab resulted in clinically meaningful improvement regardless of which prior anti-TNF agent had been used, the number of prior anti-TNFs tried, or reasons for discontinuation of prior anti-TNF therapy. Adverse event incidences were similar between patients with and without prior anti-TNF therapy.
  
  
  CONCLUSIONS
  Adalimumab was effective and well-tolerated in patients with psoriasis previously treated with anti-TNF therapy.
authors.affiliation: Department of Dermatology, University of Nice, Nice, France. ortonne@unice.fr
authors.forename: J-P
authors.initials: JP
authors.lastname: Ortonne
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
authors.forename: K
authors.initials: K
authors.lastname: Reich
authors.forename: R
authors.initials: R
authors.lastname: Gniadecki
authors.forename: P
authors.initials: P
authors.lastname: Sprøgel
authors.forename: K
authors.initials: K
authors.lastname: Unnebrink
authors.forename: H
authors.initials: H
authors.lastname: Kupper
authors.forename: O
authors.initials: O
authors.lastname: Goldblum
authors.forename: D
authors.initials: D
authors.lastname: Thaçi
mesh_terms: D000068879:Adalimumab; D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol; D000068879:Adalimumab